Join

Compare · HYPR vs TMDX

HYPR vs TMDX

Side-by-side comparison of Hyperfine Inc. (HYPR) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both HYPR and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
  • TMDX is the larger of the two at $2.94B, about 33.7x HYPR ($87.4M).
  • Over the past year, HYPR is down 31.9% and TMDX is down 25.9% - TMDX leads by 6.0 points.
  • HYPR has been more active in the news (5 items in the past 4 weeks vs 2 for TMDX).
  • TMDX has more recent analyst coverage (19 ratings vs 4 for HYPR).
PerformanceHYPR-31.88%TMDX-25.91%
2025-09-02+0.00%2026-09-01
MetricHYPRTMDX
Company
Hyperfine Inc.
TransMedics Group Inc.
Price
-
-
Market cap
$87.4M
$2.94B
1M return
-16.79%
+1.26%
1Y return
-31.88%
-25.91%
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Exchange
NASDAQ
NASDAQ
IPO
2021
2019
News (4w)
5
2
Recent ratings
4
19
HYPR

Hyperfine Inc.

Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.

TMDX

TransMedics Group Inc.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.

Latest HYPR

Latest TMDX